<DOC>
	<DOCNO>NCT00202969</DOCNO>
	<brief_summary>This open-label , multicenter , three arm , parallel , randomize , Phase 3 study evaluate efficacy safety S-1 alone compare S-1 plus CDDP , S-1 plus CDDP compare 5-FU plus CDDP patient advance gastric cancer previously untreated chemotherapy advanced disease . Patients randomly assign ( 1:1:1 ) S-1 ( Arm A ) , S-1/CDDP ( Arm B ) 5-FU/CDDP ( Arm C ) . Patients stratify achieve balance distribution patient arm accord follow stratification , performance status ( 0 , 1 , 2 ) , number metastatic site ( 1 v &gt; 1 ) , prior gastrectomy , center .</brief_summary>
	<brief_title>Study S-1 , S-1/CDDP , 5-FU/CDDP Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Nonprior chemotherapy treat advanced gastric adenocarcinoma Age 18 Performance status 0 , 1 , 2 ( ECOG ) Life expectancy 3 month Hematopoietic WBC low limit normal12,000/mm^3 Absolute granulocyte count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Hepatic AST ALT ≤ 100 U/L ALP ≤ 2 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 mg/dL Renal Plasma creatinine ≤ ULN Creatinine clearance ≥ 60 mL/min Interstitial pneumonia , pulmonary fibrosis Myocardial infarction within last 6 month , severe/unstable angina , congestive heart failure Intestinal paralysis , intestinal obstruction , uncontrollable diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Stomach cancer</keyword>
</DOC>